BIOMARIN PHARMACEUTICAL INC Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
BIOMARIN PHARMACEUTICAL INC (BMRN) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $35.85 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $35.85M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $42.61M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $48.74M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $49.47M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $35.85M 10-K · filed 2026-02-26 |
| 2024-12-31 | $42.61M 10-K · filed 2026-02-26 |
| 2023-12-31 | $48.74M 10-K · filed 2025-02-24 |
| 2022-12-31 | $49.47M 10-K · filed 2024-02-26 |
| 2021-12-31 | $50.91M 10-K · filed 2023-02-27 |
| 2020-12-31 | $47.01M 10-K · filed 2022-02-25 |
| 2019-12-31 | $42.87M 10-K · filed 2021-02-26 |
| 2018-12-31 | $35.97M 10-K · filed 2020-02-27 |
| 2017-12-31 | $31.37M 10-K · filed 2019-02-28 |
| 2016-12-31 | $47.71M 10-K · filed 2018-02-26 |
| 2015-12-31 | $49.32M 10-K · filed 2017-02-27 |
| 2014-12-31 | $34.13M 10-K · filed 2016-02-29 |
| 2013-12-31 | $29.60M 10-K · filed 2015-03-02 |
| 2012-12-31 | $22.63M 10-K · filed 2014-02-26 |
| 2011-12-31 | $22.14M 10-K · filed 2013-02-26 |
| 2010-12-31 | $17.57M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |